Pharma Deals Review, Vol 2009, No 10 (2009)

Font Size:  Small  Medium  Large

GSK Opens Rare Diseases Portfolio with Prosensa’s DMD Candidate

Taskin Ahmed

Abstract


GlaxoSmithKline (GSK) and Prosensa have agreed to develop and commercialise RNA-based therapeutics for Duchenne Muscular Dystrophy (DMD). The first drug, PRO 051, is to commence Phase III trials and signals GSK’s entry into orphan drug development.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.